Abstract
RNA-binding proteins of the Musashi (Msi) family are expressed in stem cell compartments and in aggressive tumors, but they have not yet been widely explored in the blood. Here we demonstrate that Msi2 is the predominant form expressed in hematopoietic stem cells (HSCs), and its knockdown leads to reduced engraftment and depletion of HSCs in vivo. Overexpression of human MSI2 in a mouse model increases HSC cell cycle progression and cooperates with the chronic myeloid leukemia–associated BCR-ABL1 oncoprotein to induce an aggressive leukemia. MSI2 is overexpressed in human myeloid leukemia cell lines, and its depletion leads to decreased proliferation and increased apoptosis. Expression levels in human myeloid leukemia directly correlate with decreased survival in patients with the disease, thereby defining MSI2 expression as a new prognostic marker and as a new target for therapy in acute myeloid leukemia (AML).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
Accession codes
References
Sakakibara, S. et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc. Natl. Acad. Sci. USA 99, 15194–15199 (2002).
Wang, X.Y. et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol. Cell. Biol. 28, 3589–3599 (2008).
Tenen, D.G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89–101 (2003).
Barbouti, A. et al. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res. 63, 1202–1206 (2003).
Hemmati, H.D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100, 15178–15183 (2003).
Wang, G.G., Pasillas, M.P. & Kamps, M.P. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. Mol. Cell. Biol. 26, 3902–3916 (2006).
Okano, H. et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp. Cell Res. 306, 349–356 (2005).
Kawahara, H. et al. Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PABP. J. Cell Biol. 181, 639–653 (2008).
Imai, T. et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol. Cell. Biol. 21, 3888–3900 (2001).
Kiel, M.J., Yilmaz, O.H., Iwashita, T., Terhorst, C. & Morrison, S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109–1121 (2005).
Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465–477 (2005).
Beard, C., Hochedlinger, K., Plath, K., Wutz, A. & Jaenisch, R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44, 23–28 (2006).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Wu, M. et al. Imaging hematopoietic precursor division in real time. Cell Stem Cell 1, 541–554 (2007).
Sureban, S.M. et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology 134, 1448–1458 (2008).
Huntly, B.J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
Kanai, R. et al. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum. Gene Ther. 18, 63–73 (2007).
Nikpour, P. et al. The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. J. Cell. Mol. Med. published online, doi:10.1111/j.1582-4934.2010.01090.x (14 May 2010).
Kanai, R. et al. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer–expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. J. Gene Med. 8, 1329–1340 (2006).
Creighton, C.J. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One 3, e1816 (2008).
Bild, A.H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357 (2006).
Guo, J., Jin, J. & Cooper, L.F. Dissection of sets of genes that control the character of wnt5a-deficient mouse calvarial cells. Bone 43, 961–971 (2008).
Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006).
Radich, J.P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 103, 2794–2799 (2006).
Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776–779 (2009).
Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605–1616 (2004).
Metzeler, K.H. et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112, 4193–4201 (2008).
Mullighan, C.G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
Viswanathan, S.R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843–848 (2009).
Kang, H. et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115, 1394–1405 (2009).
Rocnik, J.L. et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108, 1339–1345 (2006).
Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821–834 (2009).
Kalaitzidis, D. & Neel, B.G. Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS One 3, e3776 (2008).
Acknowledgements
We would like to thank S. Armstrong (Children's Hospital Boston) for valuable reagents. We would like to acknowledge T. Zhang, D. Kalaitzidis, K. Gritsman, P. Stern and S. Sykes for their critical suggestions and J.-A. Kwon for assistance with microarray processing. We would like to thank M. Wernig for his assistance with the project. M.G.K. was supported by the US National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award. This work was supported by grants from the NIH (D.G.G., R.J. and G.Q.D.), the Leukemia and Lymphoma Society (D.G.G. and G.Q.D.) and the Howard Hughes Medical Institute (D.G.G. and G.Q.D.). C.J.L. was supported by a Ruth L. Kirschstein Fellowship from the NIH.
Author information
Authors and Affiliations
Contributions
M.G.K. led the project, performed the experiments and wrote the manuscript; C.J.L. performed experiments and revised the manuscript; F.A.-S. performed data analysis; L.B. provided clinical samples and microarray analysis; B.B., S.Z., K.M., W.T., M.P., R.O., M.G., W.E., C.S. and S.F. performed experiments; S.W.L. and M.F. provided pathology analysis; B.L.E. provided suggestions and project oversight; D.G.G., R.J. and G.Q.D. co-directed the project and revised the manuscript.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–16, Supplementary Tables 1–5 and Supplementary Methods (PDF 3164 kb)
Rights and permissions
About this article
Cite this article
Kharas, M., Lengner, C., Al-Shahrour, F. et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 16, 903–908 (2010). https://doi.org/10.1038/nm.2187
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2187
This article is cited by
-
Asymmetric division of stem cells and its cancer relevance
Cell Regeneration (2024)
-
Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone
Annals of Hematology (2024)
-
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Molecular Cancer (2023)
-
Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition
Cell & Bioscience (2023)
-
Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation
Leukemia (2023)